CN109991410A - 一种含抗cd45单抗的组合物及其使用方法 - Google Patents
一种含抗cd45单抗的组合物及其使用方法 Download PDFInfo
- Publication number
- CN109991410A CN109991410A CN201711478332.0A CN201711478332A CN109991410A CN 109991410 A CN109991410 A CN 109991410A CN 201711478332 A CN201711478332 A CN 201711478332A CN 109991410 A CN109991410 A CN 109991410A
- Authority
- CN
- China
- Prior art keywords
- antibody
- monoclonal antibody
- composition
- monoclonal antibodies
- monoclonal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims abstract description 27
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims abstract description 27
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 15
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 11
- 230000000890 antigenic effect Effects 0.000 claims abstract description 6
- 108010013709 Leukocyte Common Antigens Proteins 0.000 claims abstract description 5
- 102000017095 Leukocyte Common Antigens Human genes 0.000 claims abstract description 5
- 239000011324 bead Substances 0.000 claims description 62
- 210000004027 cell Anatomy 0.000 claims description 38
- 239000007788 liquid Substances 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 34
- 239000008280 blood Substances 0.000 claims description 34
- 238000004140 cleaning Methods 0.000 claims description 21
- 210000004881 tumor cell Anatomy 0.000 claims description 17
- 210000003743 erythrocyte Anatomy 0.000 claims description 16
- 210000002381 plasma Anatomy 0.000 claims description 16
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 claims description 13
- 238000011534 incubation Methods 0.000 claims description 13
- 238000002372 labelling Methods 0.000 claims description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 238000005119 centrifugation Methods 0.000 claims description 10
- 241000894007 species Species 0.000 claims description 10
- 102100035716 Glycophorin-A Human genes 0.000 claims description 9
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 9
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 9
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 9
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 claims description 8
- 238000010168 coupling process Methods 0.000 claims description 7
- 238000005859 coupling reaction Methods 0.000 claims description 7
- 230000003836 peripheral circulation Effects 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 210000005266 circulating tumour cell Anatomy 0.000 abstract description 71
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 abstract description 14
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 239000000523 sample Substances 0.000 description 15
- 238000000926 separation method Methods 0.000 description 15
- 238000001514 detection method Methods 0.000 description 11
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 10
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 108010090804 Streptavidin Proteins 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 238000000432 density-gradient centrifugation Methods 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000020584 Polyploidy Diseases 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (11)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711478332.0A CN109991410B (zh) | 2017-12-29 | 2017-12-29 | 一种含抗cd45单抗的组合物及其使用方法 |
PCT/CN2018/124695 WO2019129178A1 (zh) | 2017-12-29 | 2018-12-28 | 一种含抗cd45单抗的组合物及其使用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711478332.0A CN109991410B (zh) | 2017-12-29 | 2017-12-29 | 一种含抗cd45单抗的组合物及其使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109991410A true CN109991410A (zh) | 2019-07-09 |
CN109991410B CN109991410B (zh) | 2022-07-05 |
Family
ID=67066659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711478332.0A Active CN109991410B (zh) | 2017-12-29 | 2017-12-29 | 一种含抗cd45单抗的组合物及其使用方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN109991410B (zh) |
WO (1) | WO2019129178A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114846028A (zh) * | 2019-11-01 | 2022-08-02 | 美真达治疗公司 | 抗cd45抗体及其结合物 |
CN113186161A (zh) * | 2021-03-24 | 2021-07-30 | 南京医科大学 | 快速分离超高纯度人体血液中性粒细胞的方法 |
CA3240875A1 (en) | 2021-12-23 | 2023-06-29 | Stefanie Urlinger | Discernible cell surface protein variants of cd45 for use in cell therapy |
CN114350606A (zh) * | 2022-01-05 | 2022-04-15 | 上海药明生物医药有限公司 | 一种富集大鼠浆细胞及建立浆细胞杂交瘤的方法 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030134416A1 (en) * | 2001-10-11 | 2003-07-17 | Douglas Yamanishi | Methods, compositions, and automated systems for separating rare cells from fluid samples |
AU2000263456B2 (en) * | 2000-07-14 | 2006-07-20 | Veridex, Llc | Increased separation efficiency via controlled aggregation of magnetic nanoparticles |
WO2007121465A2 (en) * | 2006-04-18 | 2007-10-25 | Wellstat Biologics Corporation | Detection of proteins from circulating neoplastic cells |
CN101939648A (zh) * | 2008-01-07 | 2011-01-05 | 卢米耐克斯公司 | 生物靶标的免疫磁性捕获和成像 |
US20130189675A1 (en) * | 2011-07-21 | 2013-07-25 | Steven Gross | Assay to Capture and Detect Circulating Multiple Myeloma Cells from Blood |
RU131494U1 (ru) * | 2012-11-02 | 2013-08-20 | Общество с ограниченной ответственностью "ИммуноСлайд" | Биочип для исследования клеток крови и костного мозга |
CN103725648A (zh) * | 2013-09-28 | 2014-04-16 | 长沙赢润生物技术有限公司 | 一种新的循环肿瘤细胞富集技术及试剂盒制备方法 |
CN104178454A (zh) * | 2013-05-24 | 2014-12-03 | 益善生物技术股份有限公司 | 一种循环肿瘤细胞的富集、分析方法 |
US20150132738A1 (en) * | 2011-11-01 | 2015-05-14 | Yanping Li | Method For Identification Of Non-Hematogeneous Karocytes Enriched From Body Fluid Of Humans Or Animals |
CN105026934A (zh) * | 2013-03-15 | 2015-11-04 | 詹森诊断器材有限责任公司 | 通过耗尽白血细胞富集循环肿瘤细胞 |
CN105067808A (zh) * | 2015-07-30 | 2015-11-18 | 南京医科大学 | 一种高纯度循环肿瘤细胞的富集方法及试剂盒 |
CN105675378A (zh) * | 2014-11-18 | 2016-06-15 | 上海张江转化医学研发中心有限公司 | 一种简单的分离单个循环肿瘤细胞的方法和装置 |
CN105807057A (zh) * | 2016-03-11 | 2016-07-27 | 武汉大学 | 一种捕获和鉴定循环肿瘤细胞同步进行的方法 |
CN106198963A (zh) * | 2016-08-31 | 2016-12-07 | 上海美吉生物医药科技有限公司 | 一种用于捕获白细胞的免疫磁珠及其制备方法 |
WO2017020617A1 (zh) * | 2015-07-31 | 2017-02-09 | 上海交通大学 | 循环肿瘤细胞检测方法和装置 |
US20170335001A1 (en) * | 2010-06-18 | 2017-11-23 | Kalobios Pharmaceuticals, Inc. | Detection of EphA3 as a Marker of the Presence of a Solid Tumor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105087788B (zh) * | 2015-08-03 | 2018-11-23 | 上海白泽医疗器械有限公司 | 一种分选人细胞的免疫磁珠、其制备及切除方法 |
CN106244553A (zh) * | 2015-10-22 | 2016-12-21 | 厦门人瑞生物医药科技有限公司 | 循环肿瘤细胞的分离和检测方法 |
-
2017
- 2017-12-29 CN CN201711478332.0A patent/CN109991410B/zh active Active
-
2018
- 2018-12-28 WO PCT/CN2018/124695 patent/WO2019129178A1/zh active Application Filing
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2000263456B2 (en) * | 2000-07-14 | 2006-07-20 | Veridex, Llc | Increased separation efficiency via controlled aggregation of magnetic nanoparticles |
US20030134416A1 (en) * | 2001-10-11 | 2003-07-17 | Douglas Yamanishi | Methods, compositions, and automated systems for separating rare cells from fluid samples |
WO2007121465A2 (en) * | 2006-04-18 | 2007-10-25 | Wellstat Biologics Corporation | Detection of proteins from circulating neoplastic cells |
CN101939648A (zh) * | 2008-01-07 | 2011-01-05 | 卢米耐克斯公司 | 生物靶标的免疫磁性捕获和成像 |
US20170335001A1 (en) * | 2010-06-18 | 2017-11-23 | Kalobios Pharmaceuticals, Inc. | Detection of EphA3 as a Marker of the Presence of a Solid Tumor |
US20130189675A1 (en) * | 2011-07-21 | 2013-07-25 | Steven Gross | Assay to Capture and Detect Circulating Multiple Myeloma Cells from Blood |
US20150132738A1 (en) * | 2011-11-01 | 2015-05-14 | Yanping Li | Method For Identification Of Non-Hematogeneous Karocytes Enriched From Body Fluid Of Humans Or Animals |
RU131494U1 (ru) * | 2012-11-02 | 2013-08-20 | Общество с ограниченной ответственностью "ИммуноСлайд" | Биочип для исследования клеток крови и костного мозга |
CN105026934A (zh) * | 2013-03-15 | 2015-11-04 | 詹森诊断器材有限责任公司 | 通过耗尽白血细胞富集循环肿瘤细胞 |
CN104178454A (zh) * | 2013-05-24 | 2014-12-03 | 益善生物技术股份有限公司 | 一种循环肿瘤细胞的富集、分析方法 |
CN103725648A (zh) * | 2013-09-28 | 2014-04-16 | 长沙赢润生物技术有限公司 | 一种新的循环肿瘤细胞富集技术及试剂盒制备方法 |
CN105675378A (zh) * | 2014-11-18 | 2016-06-15 | 上海张江转化医学研发中心有限公司 | 一种简单的分离单个循环肿瘤细胞的方法和装置 |
CN105067808A (zh) * | 2015-07-30 | 2015-11-18 | 南京医科大学 | 一种高纯度循环肿瘤细胞的富集方法及试剂盒 |
WO2017020617A1 (zh) * | 2015-07-31 | 2017-02-09 | 上海交通大学 | 循环肿瘤细胞检测方法和装置 |
CN105807057A (zh) * | 2016-03-11 | 2016-07-27 | 武汉大学 | 一种捕获和鉴定循环肿瘤细胞同步进行的方法 |
CN106198963A (zh) * | 2016-08-31 | 2016-12-07 | 上海美吉生物医药科技有限公司 | 一种用于捕获白细胞的免疫磁珠及其制备方法 |
Non-Patent Citations (2)
Title |
---|
MORTEN LAPIN等: "MINDEC-An Enhanced Negative Depletion Strategy for Circulating Tumor Cell Enrichment", 《SCIENTIFIC REPORT》 * |
白炎: "人白细胞分化抗原研究进展", 《免疫学杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN109991410B (zh) | 2022-07-05 |
WO2019129178A1 (zh) | 2019-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109991410A (zh) | 一种含抗cd45单抗的组合物及其使用方法 | |
US20020164825A1 (en) | Cell separation matrix | |
Frøland et al. | Human lymphocytes with receptors for IgG: A population of cells distinct from T-and B-lymphocytes | |
CN105388055B (zh) | 从尿液中分离肿瘤细胞来源的外泌体的方法 | |
CN107245472A (zh) | 一种人间充质干细胞外泌体冻干粉的制备方法、使用方法 | |
CN107988153A (zh) | 人脐带血间充质干细胞源分离外泌体的方法和使用的试剂 | |
CN109856388A (zh) | 循环肿瘤细胞的捕获方法及捕获试剂盒 | |
CN113136362B (zh) | 一种囊泡及其应用 | |
CN105087493B (zh) | 联用三种单克隆抗体偶联免疫磁珠在肿瘤细胞分选中应用 | |
CN110419505A (zh) | 小鼠食管癌模型及其建立方法 | |
CN106244553A (zh) | 循环肿瘤细胞的分离和检测方法 | |
CN106047804B (zh) | 一种脂肪干细胞的纯化方法及干细胞在成骨诱导及成软骨诱导上的应用 | |
CN107356744A (zh) | 一种循环肿瘤细胞分选和/或富集的方法及其试剂盒 | |
CN110456034A (zh) | 一种循环肿瘤细胞的检测方法 | |
CN114765957A (zh) | 从羊水中获得羊膜间充质干细胞的方法和设备及其来源的细胞 | |
CN108148809A (zh) | 一种从肿瘤细胞上清液中分离外泌体的方法 | |
CN111351937A (zh) | 一种mmr蛋白表达缺失检测试剂盒及其检测方法 | |
CN102492654A (zh) | 一种分离人脐带血干细胞的试剂盒及其使用方法 | |
Lim et al. | Identification of stromal cells in spleen which support myelopoiesis | |
CN109507427A (zh) | 一种基于高亲和力cd45兔单抗的循环肿瘤细胞高效富集方法及其应用 | |
JP2011515084A (ja) | 幹細胞を生成するための血液、好ましくは末梢血を採取するためのキット | |
CN108220233A (zh) | 细胞分离器具表面处理方法、相关器具、外周血稀有细胞或循环肿瘤细胞快速高效分离方法 | |
CN106350489A (zh) | 人骨髓、脐带血、外周血干细胞分离试剂盒及其分离方法 | |
CN111893086B (zh) | 胎儿有核红细胞捕获载体、提取装置及方法 | |
Campos et al. | Expression of CD 19 antigen on acute monoblastic leukemia cells at diagnosis and after TPA-induced differentiation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 201805 floor 1, building 7, No. 1585, Yuanguo Road, Anting Town, Jiading District, Shanghai Patentee after: SHANGHAI BAIZE MEDICAL LABORATORY Co.,Ltd. Country or region after: China Patentee after: SHANGHAI CELL THERAPY Research Institute Patentee after: Shanghai Cell Therapy Group Co.,Ltd. Address before: 201805 floor 1, building 7, No. 1585, Yuanguo Road, Anting Town, Jiading District, Shanghai Patentee before: SHANGHAI BAIZE MEDICAL LABORATORY Co.,Ltd. Country or region before: China Patentee before: SHANGHAI CELL THERAPY Research Institute Patentee before: SHANGHAI CELL THERAPY GROUP Co.,Ltd. |